Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I3XA
|
|||
| Former ID |
DNC002338
|
|||
| Drug Name |
Ciproxifan
|
|||
| Synonyms |
ciproxifan; 184025-18-1; FUB-359; FUB 359; FUB359; UNII-5EVQ7IRG99; 5EVQ7IRG99; CHEMBL14638; ACQBHJXEAYTHCY-UHFFFAOYSA-N; cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone; (4-(3-(1H-imidazol-4-yl)propoxy)phenyl)(cyclopropyl)methanone; Ciproxifan; FUB 359; Methanone, cyclopropyl(4-(3-(1H-imidazol-5-yl)propoxy)phenyl)-; Ciproxifan (FUB-359); AC1O4Y0P; GTPL1265; SCHEMBL3335184; BDBM27213; EX-A077; DTXSID50171532; cyclopropyl-(4-(3-1H-imidazol-4-yl)propyloxyphenyl)ketone; CHEBI:125467; MolPort-027-720-958; ZINC1892860
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Dementia [ICD-11: 6D80-6D86] | Investigative | [1] | |
| Obesity [ICD-11: 5B81; ICD-10: E66] | Investigative | [1] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H18N2O2
|
|||
| Canonical SMILES |
C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3
|
|||
| InChI |
1S/C16H18N2O2/c19-16(12-3-4-12)13-5-7-15(8-6-13)20-9-1-2-14-10-17-11-18-14/h5-8,10-12H,1-4,9H2,(H,17,18)
|
|||
| InChIKey |
ACQBHJXEAYTHCY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 184025-18-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14774960, 29217532, 29217533, 43016263, 47434879, 47583760, 50070539, 50071174, 52113953, 53790071, 57298923, 57304380, 57366836, 85209025, 90341100, 103177393, 114520252, 123051072, 127387036, 131549292, 135323023, 135650102, 137007869, 137156933, 144235387, 152258581, 160647417, 162205198, 163641900, 177749578, 186014464, 189024876, 198972741, 198993150, 225089285, 229360424, 242060244, 249979315, 251883549
|
|||
| ChEBI ID |
CHEBI:125467
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 3 receptor (5HT3R) | Target Info | Antagonist | [2] |
| Adrenergic receptor alpha-2A (ADRA2A) | Target Info | Antagonist | [2] | |
| Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Antagonist | [2] | |
| Histamine H3 receptor (H3R) | Target Info | Antagonist | [2] | |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| Histamine receptors | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Monoamine Transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1265). | |||
| REF 2 | The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.